Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab dose-ranging study in adults with moderate-to-severe asthma
2023-508039-29-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Rocatinlimab with Placebo (2 arms). Primary endpoint: Annualized asthma exacerbation rate during the placebo-controlled treatment period. Started Sep 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-508039-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508039-29-00.